Defining Retinal Structures Using Hyperspectral Retinal Imaging
NCT07555574
Summary
This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography. Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
Eligibility
Inclusion Criteria: * Adults aged 18 years and older * Able to provide informed consent * Willing and able to attend a study visit at the Centre for Eye Research Australia * Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration) * Age- and sex-matched healthy control participants without known retinal or optic nerve disease Exclusion Criteria: * Inability to provide informed consent * Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage) * Known contraindication to pharmacological pupil dilation * History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe * Any condition that, in the investigator's opinion, would compromise participant safety or image quality
Conditions6
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07555574